A phase I trial of chlorambucil administered in short pulses in patients with advanced malignancies

Martin S. Blumenreich, Thomas M. Woodcock, Eliza J. Sherrill, Stephen P. Richman, Patrick S. Gentile, Barbara E. Epremian, Thomas T. Kubota, Joseph C. Allegra

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


We carried out a phase I trial with chlorambucil. Thirty patients with advanced cancer were entered in six dose levels: 36, 48, 60, 84, 108, and 144 mg/m2. The drug was given in six divided oral doses every 6 hours and the regimen was repeated every 3 weeks. The median age was 62 years (31-84), median Kamofsky performance status (KPS) 60 (40-90). All patients but one had received prior radiation therapy, chemotherapy, or both. Central nervous system toxicity was dose limiting, occurring in 5 of 6 patients at 144 mg/m2. It was characterized by transient seizures, hallucinations, lethargy, stupor, and coma. Metoclopramide was successful in controlling nausea and vomiting, which was severe if the antiemetic was not used. Leukopenia (3 patients) and thrombocytopenia (2 patients) were mild. One patient with colorectal carcinoma had a minor response, and two patients with non-small cell lung cancer had stable disease. A safe dose for phase II trials is 108 mg/m2 in six 6-hourly oral doses.

Original languageEnglish (US)
Pages (from-to)371-375
Number of pages5
JournalCancer Investigation
Issue number4
StatePublished - Jan 1 1988
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'A phase I trial of chlorambucil administered in short pulses in patients with advanced malignancies'. Together they form a unique fingerprint.

Cite this